NTLA
Intellia Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.78B
P/E Ratio
—
EPS
$-3.52
Beta
1.81
52W High
$28.25
52W Low
$7.95
50-Day MA
$13.65
200-Day MA
$13.39
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
-0.10
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $66.09M |
| Gross Profit (TTM) | $-230.67M |
| EBITDA | $-411.24M |
| Operating Margin | -668.00% |
| Return on Equity | -56.30% |
| Return on Assets | -30.10% |
| Revenue/Share (TTM) | $0.59 |
| Book Value | $5.16 |
| Price-to-Book | 2.78 |
| Price-to-Sales (TTM) | 26.91 |
| EV/Revenue | 21.65 |
| EV/EBITDA | -5.51 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -9.50% |
| Shares Outstanding | $139.72M |
| Float | $134.16M |
| % Insiders | 3.83% |
| % Institutions | 76.74% |
Historical Volatility
HV 10-Day
90.03%
HV 20-Day
80.05%
HV 30-Day
74.63%
HV 60-Day
77.70%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($26.63 target)
1
Strong Buy11
Buy9
Hold1
Sell1
Strong SellMore HEALTHCARE Stocks
Data last updated: 6/13/2026